InhaleRx Limited (AU:IRX) has released an update.
InhaleRx Ltd, an Australian healthcare firm specializing in inhaled therapies for pain management and mental health, announced a live investor webinar with CEO Darryl Davies to discuss the company’s progress and answer shareholder questions. The goal of the company is to secure U.S. FDA approval for their products targeting underserved medical conditions, such as Breakthrough Cancer Pain and Panic Disorder. InhaleRx is also focusing on strengthening its patent portfolio for these treatments.
For further insights into AU:IRX stock, check out TipRanks’ Stock Analysis page.